| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 21.10. | Lobe Sciences Ltd (2): Lobe Sciences appoints Goeken as chief medical officer | 1 | Stockwatch | ||
| LOBE SCIENCES Aktie jetzt für 0€ handeln | |||||
| 20.10. | Lobe Sciences Ltd.: Lobe Sciences Appoints Tracy L. Goeken, M.D., as Chief Medical Officer | 370 | ACCESS Newswire | Physician executive brings clinical development and regulatory experience in generalized anxiety disorder and sickle cell diseaseCompany also engages Independent Trading Group (ITG) to provide market-making... ► Artikel lesen | |
| 14.10. | Lobe Sciences Ltd (2): Lobe Sciences appoints Grimaldi as director | 1 | Stockwatch | ||
| 14.10. | Lobe Sciences Ltd.: Lobe Sciences Appoints Annette Grimaldi, Former Head of Life Sciences Investment Banking at BMO Capital Markets, to Board of Directors | 274 | ACCESS Newswire | Executive with three decades of life sciences financing and M&A experience joins the board as Lobe advances L-130 in anxiety and cluster headache and S-100 in sickle cell disease VANCOUVER, BC / ACCESS... ► Artikel lesen | |
| 08.10. | Lobe Sciences Ltd (2): Lobe Sciences to make moves in IR, PR and directorships | 1 | Stockwatch | ||
| 08.10. | Lobe Sciences Ltd.: Lobe Sciences Announces Proposed Capital Markets Initiatives to Support Planned Growth | 339 | ACCESS Newswire | Company intends to initiate independent market-making services, expanded investor and media outreach, and add board expertise in Canadian and U.S. capital markets VANCOUVER, BC / ACCESS Newswire / October... ► Artikel lesen | |
| 15.09. | Lobe Sciences Ltd.: Lobe Sciences to Present Low-Dose L-130 Clinical Data at 9th Neuropsychiatric Drug Development Summit | 521 | ACCESS Newswire | ? Dr. Frederick D. Sancilio to present "Reimagining Psychedelic Therapeutics for Daily Outpatient Use: Advancing Low-Dose Psilocin Beyond the Hallucinogenic Paradigm" on Wednesday, September 16? Presentation... ► Artikel lesen | |
| 14.09. | ArcStone US Corp.: Lobe Sciences to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto | 500 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - September 14, 2026) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) (FSE: LOBE.F) ("Lobe" or the "Company") is pleased to announce its participation in... ► Artikel lesen | |
| 01.09. | Lobe Sciences Ltd. Announces Closing of Upsize to Non-Brokered Private Placement | 654 | ACCESS Newswire | NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESS Newswire / August 31, 2026 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F)... ► Artikel lesen | |
| 29.08. | Lobe Sciences Ltd (2): Lobe Sciences increases private placement to $2.16M | 2 | Stockwatch | ||
| 29.08. | Lobe Sciences Ltd. Announces Upsize to Non-Brokered Private Placement | 661 | ACCESS Newswire | NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, BC / ACCESS Newswire / August 28, 2026 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE)... ► Artikel lesen | |
| 28.08. | Lobe Sciences Ltd (2): Lobe Sciences appoints Kideckel as CFO | 1 | Stockwatch | ||
| 28.08. | Lobe Sciences Ltd.: Lobe Sciences Expands Leadership Team with New CFO Appointment | 413 | ACCESS Newswire | Dr. David Kideckel, PhD, MBA, joins as Chief Financial Officer, bringing nearly two decades of life sciences, capital markets and corporate advisory experienceCurrent CFO, Mirza Rahimani, transitions... ► Artikel lesen | |
| 20.08. | Lobe Sciences Ltd (2): Lobe Sciences closes $2.1-million private placement | 1 | Stockwatch | ||
| 20.08. | Lobe Sciences Ltd. Announces Closing of Non-Brokered Private Placement | 328 | ACCESS Newswire | NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, BC / ACCESS Newswire / August 20, 2026 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE)... ► Artikel lesen | |
| 19.08. | Lobe Sciences reports Q3 results | 1 | Seeking Alpha | ||
| 18.08. | Lobe Sciences Ltd.: Lobe Sciences Reports Third Quarter 2026 Financial Results | 326 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / August 18, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F) ("Lobe" or the "Company"), a clinical-stage biopharmaceutical company advancing therapeutic... ► Artikel lesen | |
| 13.08. | Lobe Sciences Ltd (2): Lobe Sciences arranges $2.1-million private placement | 1 | Stockwatch | ||
| 12.08. | Lobe Sciences to raise C$2.1M in private placement | 3 | Seeking Alpha | ||
| 12.08. | Lobe Sciences Ltd. Announces Non-Brokered Private Placement | 642 | ACCESS Newswire | NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, BC / ACCESS Newswire / August 12, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FSE:LOBE.F) ("Lobe"... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONXT SOLUTIONS | 0,156 | +0,32 % | BioNxt: Beyond the Pill.. Could Dissolvable Film Technology Change Multiple Sclerosis Treatment? | Join Lyndsay Malchuk on Market Frontlines for an interview with Hugh Rogers, Co-Founder, CEO and Director of BioNxt Solutions Inc. (CSE: BNXT | OTCQB: BNXTF | FSE: BXT). BioNxt develops sublingual dissolvable... ► Artikel lesen | |
| AMYRIS | - | - | Sugar replacement maker Oobli acquired by biotech firm Amyris | ||
| HELUS PHARMA | 6,190 | -5,35 % | Helus shares slide on psychedelic readout in depression | ||
| SOL GLOBAL INVESTMENTS | 0,026 | -100,00 % | SOL Global Investments Corp.: SOL Global Announces Resignation of Deena Siblock and Conclusion of Consulting Arrangement | Toronto, Ontario--(Newsfile Corp. - October 26, 2026) - SOL GLOBAL INVESTMENTS CORP. (CSE: SOL) (OTC Pink: SOLCF) (FSE: 9SB0) ("SOL Global" or the "Company") announces that Deena Siblock has resigned... ► Artikel lesen | |
| ENTHEON BIOMEDICAL CORP | 0,031 | 0,00 % | Entheon Biomedical Corp.: Entheon Announces Continuance into British Columbia | Vancouver, British Columbia--(Newsfile Corp. - October 8, 2026) - Entheon Biomedical Corp. (CSE: ENBI.X) (OTCID: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") is pleased to announce that it has continued... ► Artikel lesen | |
| REVIVE THERAPEUTICS | 0,002 | 0,00 % | Revive Therapeutics Ltd.: Revive Therapeutics to Expand Bucillamine IP and Orphan Drug Portfolio Across Medical Countermeasures and Rare Diseases | Company aims to build a globally protected bucillamine franchise spanning medical countermeasures, orphan diseases and government preparedness programs TORONTO, ON / ACCESS Newswire / September 15,... ► Artikel lesen | |
| RAPID DOSE THERAPEUTICS | - | - | Rapid Dose Therapeutics Corp.: Rapid Dose Announces Proposed Debt Settlement | Burlington, Ontario--(Newsfile Corp. - October 30, 2026) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF) ("RDT" or the "Company") announces that it has agreed with certain of its creditors... ► Artikel lesen | |
| QIAGEN | 45,200 | 0,00 % | QIAGEN N.V.: QIAGEN Shareholders Overwhelmingly Approve Jonathan M. Pratt as Managing Director | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that shareholders overwhelmingly approved the appointment of Jonathan M. Pratt as a Managing Director and member of the QIAGEN... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 10,500 | 0,00 % | Summit Therapeutics (SMMT) Is Losing Wall Street's Confidence | ||
| DISC MEDICINE | 77,98 | 0,00 % | Disc Medicine auf der Jefferies Global Healthcare Conference: Bitopertin auf Erholungskurs | ||
| TANGO THERAPEUTICS | 21,890 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| CG ONCOLOGY | 80,01 | +0,01 % | Truist hebt Kursziel für CG Oncology nach Studiendaten an | ||
| ERASCA | 13,780 | +0,15 % | Erasca, Bristol Myers Squibb Partner To Study Combination Therapy In Pancreatic Cancer | NEW YORK CITY (dpa-AFX) - Erasca, Inc. (ERAS) announced a clinical trial collaboration with Bristol Myers Squibb (BMY) to evaluate ERAS-0015, Erasca's investigational pan-RAS molecular glue... ► Artikel lesen | |
| BEAM THERAPEUTICS | 21,020 | +0,05 % | Beam Therapeutics auf UBS-Konferenz: Forcierte Plattformstrategie und BLA-Antrag für Sichelzelltherapie in Sicht | ||
| PRAXIS PRECISION MEDICINES | 304,85 | -0,11 % | Guggenheim hebt Kursziel für Praxis Precision Medicines auf 1.050 $ an - Kaufempfehlung bestätigt |